Minapharm Acquires Majority Stake In ProBioGen

Cairo-based Minapharm is a manufacturer and marketer of specialty pharmaceuticals and, through its subsidiary Rhein Minapharm Biogenetics, is in the research, development and manufacturing of biopharmaceuticals.

ProBioGen will continue to be a committed technology and service provider for its global biopharmaceutical clients. The company will also continue to develop proprietary technologies in the field of biopharmaceutical products.

Meanwhile, ProBioGen has appointed Dr Wieland Wolf as new CEO. He joined from Rentschler Biotechnologie, where he was a member of the management board. Dr Wolf is also president of the European Association of Pharma Biotechnology.

He takes over responsibilities from Michael Schlenk, who joined the company in a Management Buy-In.

Wafik Bardissi, chairman and CEO of Minapharm, and newly elected chairman of the supervisory board of ProBioGen, said: “After a long history of successful cooperation with ProBioGen we highly appreciate its reputation and dedication to service excellence, which will remain the focus of its business. This transaction is a boost to Minapharm’s thriving biotech operations and fosters a futuristic model of innovation internationally including the developing world.”

Volker Sandig, CSO of ProBioGen, said: “The new ownership gives both companies increased leeway to accelerate the growth of their businesses and to strengthen their market position. Minapharm has a broad and exciting product pipeline and we are looking forward to supporting the development with our enabling technologies.”